8-K - Cocrystal Pharma, Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Cocrystal Pharma, Inc. announced that the first subjects have been dosed in its Phase 1b norovirus challenge study evaluating CDI-988 as a preventive and treatment for norovirus infections at Emory University School of Medicine. This milestone advances the first oral antiviral drug candidate targeting norovirus 3CL protease amid a significant unmet medical need.

Key Takeaways

1First subjects dosed in Phase 1b norovirus challenge study (NCT07198139) on March 9, 2026

2Study evaluates CDI-988 for prevention and treatment of GII.2 (Snow Mountain Virus) norovirus infections

3Randomized, double-blind, placebo-controlled trial enrolling up to 40 healthy subjects ages 18–49

4Primary endpoint: efficacy in reducing clinical symptoms vs placebo; secondary: viral shedding, disease severity, safety, PK

5CDI-988 previously safe in Phase 1 up to 1200 mg dose; FDA Study May Proceed Letter in September 2025

6Study at Emory University School of Medicine; first direct-acting antiviral trial for norovirus

Current Report Details

Event Type

Regulation Fd

Exhibits Only

Disclosure

Voluntary

Variant

8-K

Items Reported

7.01

(including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject

Regulation Fd

9.01

Financial Statements and Exhibits. (d) Exhibits Exhibit Description 99.1 Press Release dated March 9, 2026 104 Cover Page Interactive Data File (embedded within

Exhibits Only

Source Document

Exhibits (2)

8-K

99.1

EX-99.1